We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer.

We are quickly and efficiently advancing multiple programs with clinical development underway for influenza, norovirus and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications.

Media

Developing Broad Spectrum Antiviral Drugs and Rising Threat from Avian Flu with Dr. Sam Lee Cocrystal Pharma

October 31, 2024

Conversation with Jim Martin, Co-CEO of Cocrystal Pharma

October 28, 2024

Innovative Approaches to Antiviral Drug Development

October 16, 2024

EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs

Cocrystal Pharma Discusses Antiviral Therapeutics, Clinical Development and 2024 Value Catalysts in CEO Video Interview

March 4, 2024

COCP - Jim Martin Interview

February 7, 2024

Novel Antiviral Drug Shows Promise Treating Norovirus with Dr. Sam Lee Cocrystal Pharma

December 18, 2023

Novel Antiviral Drug Shows Promise Treating Norovirus with Dr. Sam Lee Cocrystal Pharma TRANSCRIPT

December 18, 2023

Jim Martin, Co-CEO & CFO Of Cocrystal Pharma Is Fighting The FLU, C-19, & Other Diseases

September 6, 2023

Seattle company founded by Nobel Prize winner plans human tests for experimental COVID-19 drug

August 14, 2023

Cocrystal Pharma Picks Novel Oral Protease Inhibitor CDI-988 As Norovirus Lead

August 11, 2023

Cross-Spectrum Anti-Viral Compounds Needed for Seasonal and Pandemic Infections with Sam Lee Cocrystal Pharma on Empowered Patient with Karen Jagoda

March 15, 2023

Cross-Spectrum Anti-Viral Compounds Needed for Seasonal and Pandemic Infections with Sam Lee Cocrystal Pharma on Empowered Patient with Karen Jagoda TRANSCRIPT

March 15, 2023

The Big Biz Show

February 16, 2023

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

January 23, 2023

Cocrystal Pharma Partners With hVIVO in New Antiviral Flu Treatment Phase 2 Trial

IDSE Infectious Disease Special Edition

August 8, 2022

Cocrystal Antiviral Flu Candidate Shows Potential for Once-Daily Treatment in Phase 1 Trial

IDSE Infectious Disease Special Edition

July 22, 2022

Life Science Leader

CoCrystal's Co-Ceos

June 6, 2022

Cocrystal, NIAID expand partnership for Covid-19 protease inhibitors Pharmaceutical Technology

June 2, 2022

Empowered Patient Podcast with Karen Jagoda

Drug Development Platform Creating Novel Antiviral Therapeutics for Pandemics and Seasonal Influenza with Sam Lee and Jim Martin Cocrystal Pharma

May 8, 2022

Cocrystal Pharma advancing programs in high-value antiviral drug targets

BioTuesday.com

April 4, 2022

Cocrystal’s Proprietary Technologies in Antiviral Therapeutics to Combat COVID-19

October 11, 2021

C-Suite Interview with Cocrystal Pharma (COCP) Interim Co-CEOs Sam Lee, President & James Martin, CFO

June 9, 2021